# US 6,730,295 B2 · Anionic polymers as species specific antibacterial agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,295 B2
- Document ID: US6730295B2
- Status: Granted
- Kind: B2
- Application number: 09/847,053
- Filed: 2001-05-01
- Published: 2002-03-21
- Granted: 2004-05-04
- Earliest claimed: 2000-05-02
- Assignees: Genzyme Corporation
- Inventors: Richard J. Fitzpatrick; Robert H. Barker, Jr.
- Web page: https://patentgrep.com/patent/US6730295B2

## CPC

- A61K 31/795: Polymers containing sulfur
- A61K 31/80: Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
- A61P 31/04: Antibacterial agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to the discovery that certain anionic polymers have useful antibacterial activity.

## Claims

### Claim 1

A method of treating a bacterial infection in a patient, comprising administering to the patient a therapeutically effective amount of a polymer selected from the group consisting of poly(undecenesulfate), poly(undecenephosphate), poly(undecenesulfonate), poly(styrenesulfonate, poly(undecenoic acid), poly(undecenoic acid-co-undecenesulfate) and poly(mono-C2-C12-alkylmaleic acid).

### Claim 2 (depends on 1)

The method of claim 1 wherein the bacterial infection is an infection by a bacterial species selected from the group consisting of Neisseria species and Moraxella species.

### Claim 3 (depends on 2)

The method of claim 2 wherein the bacterial infection is an infection by Neisseria meningitidis or Moraxella catarrhalis.

### Claim 4 (depends on 1)

The method of claim 1 wherein the bacteria infection is an infection by Streptococcus sanguis and the polymer which is administered is poly(styrene sulfonate), poly(undecensulfate) or poly(undecensulfonate).

### Claim 5 (depends on 4)

The method of claim 4 wherein the polymer is poly(styrene sulfonate, Na+).

### Claim 6 (depends on 5)

The method of claim 5 wherein the polymer has a molecular weight less than about 700,000 daltons.

### Claim 7 (depends on 6)

The method of claim 6 wherein the polymer has a molecular weight less than about 500,000 daltons.

### Claim 8 (depends on 7)

The method of claim 7 wherein the polymer has a molecular weight less than about 400,000 daltons.

### Claim 9 (depends on 1)

The method of claim 1 wherein the bacterial infection is an infection by Streptococcus pneumoniae and the polymer which is administered is poly(undecenesulfonate), poly(undecenesulfate) or poly(undecenoic acid-co-undecenesulfate).

### Claim 10 (depends on 1)

The method of claim 1 wherein the bacterial infection is an infection by Neisseria meningitidis and the polymer which is administered is poly(styrene sulfonate), poly(undecenesulfonate), poly(undecenesulfate), poly(undecenoic acid-co-undecenesulfate) or poly(mono-C2-C2-alkylmaleic acid).

### Claim 11 (depends on 10)

The method of claim 10 wherein the polymer is poly(monodecylmaleic acid).

### Claim 12 (depends on 1)

The method of claim 1 wherein the infection is an infection by Moraxella catarhalis, and the polymer which is administered is poly(styrenesulfonate), poly(undecenoic acid), poly(undecenesulfate), and poly(undecenoic acid-co-undecenesulfate).
